These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 15477320)
1. Hormone replacement and breast cancer. Castiglione-Gertsch M Ann Oncol; 2004; 15 Suppl 4():iv275-7. PubMed ID: 15477320 [No Abstract] [Full Text] [Related]
2. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits. Gordhandas S; Norquist BM; Pennington KP; Yung RL; Laya MB; Swisher EM Gynecol Oncol; 2019 Apr; 153(1):192-200. PubMed ID: 30661763 [TBL] [Abstract][Full Text] [Related]
3. Hormone Therapy in Breast Cancer Survivors and Those at High Risk for Breast Cancer. Reid RL Clin Obstet Gynecol; 2018 Sep; 61(3):480-487. PubMed ID: 29750683 [TBL] [Abstract][Full Text] [Related]
4. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status. Shah PD; Patil S; Dickler MN; Offit K; Hudis CA; Robson ME Cancer; 2016 Apr; 122(8):1178-84. PubMed ID: 26859126 [TBL] [Abstract][Full Text] [Related]
5. Hormonal prevention of hereditary breast cancer. Narod SA Ann N Y Acad Sci; 2001 Dec; 952():36-43. PubMed ID: 11795442 [TBL] [Abstract][Full Text] [Related]
7. Radiotherapy for breast cancer in BRCA1/BRCA2 carriers: clinical issues and management dilemmas. Pierce L Semin Radiat Oncol; 2002 Oct; 12(4):352-61. PubMed ID: 12382193 [TBL] [Abstract][Full Text] [Related]
8. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Gronwald J; Tung N; Foulkes WD; Offit K; Gershoni R; Daly M; Kim-Sing C; Olsson H; Ainsworth P; Eisen A; Saal H; Friedman E; Olopade O; Osborne M; Weitzel J; Lynch H; Ghadirian P; Lubinski J; Sun P; Narod SA; Int J Cancer; 2006 May; 118(9):2281-4. PubMed ID: 16331614 [TBL] [Abstract][Full Text] [Related]
9. Genetic risk in context: calculating the penetrance of BRCA1 and BRCA2 mutations. Burke W; Austin MA J Natl Cancer Inst; 2002 Aug; 94(16):1185-7. PubMed ID: 12189215 [No Abstract] [Full Text] [Related]
10. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742 [TBL] [Abstract][Full Text] [Related]
11. Clinical management of women with genomic BRCA1 and BRCA2 mutations. Chang J; Elledge RM Breast Cancer Res Treat; 2001 Sep; 69(2):101-13. PubMed ID: 11759816 [TBL] [Abstract][Full Text] [Related]
12. Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. Chang-Claude J; Andrieu N; Rookus M; Brohet R; Antoniou AC; Peock S; Davidson R; Izatt L; Cole T; Noguès C; Luporsi E; Huiart L; Hoogerbrugge N; Van Leeuwen FE; Osorio A; Eyfjord J; Radice P; Goldgar DE; Easton DF; ; ; ; Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):740-6. PubMed ID: 17416765 [TBL] [Abstract][Full Text] [Related]
13. Inherited predisposition and breast cancer: modifiers of BRCA1/2-associated breast cancer risk. Rebbeck TR Environ Mol Mutagen; 2002; 39(2-3):228-34. PubMed ID: 11921193 [TBL] [Abstract][Full Text] [Related]
14. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Chenevix-Trench G; Milne RL; Antoniou AC; Couch FJ; Easton DF; Goldgar DE; Breast Cancer Res; 2007; 9(2):104. PubMed ID: 17466083 [TBL] [Abstract][Full Text] [Related]
15. Breast cancer risks: some clinically useful approaches. Kelly PT Curr Womens Health Rep; 2002 Apr; 2(2):128-33. PubMed ID: 12116602 [TBL] [Abstract][Full Text] [Related]
16. Oophorectomy for breast cancer prevention in women with BRCA1 or BRCA2 mutations. Metcalfe KA Womens Health (Lond); 2009 Jan; 5(1):63-8. PubMed ID: 19102642 [TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2: to test or not to test. Brandt RT; Lynch HT Breast Cancer Res Treat; 2001 May; 67(2):187-8. PubMed ID: 11519868 [No Abstract] [Full Text] [Related]
18. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer. Spannuth WA; Thaker PH; Sood AK Am J Obstet Gynecol; 2007 Apr; 196(4):e6-9. PubMed ID: 17403394 [TBL] [Abstract][Full Text] [Related]
19. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A; Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006 [TBL] [Abstract][Full Text] [Related]
20. Management of early-onset breast cancer and BRCA1 or BRCA2 status. Vaidya JS; Baum M Lancet; 2002 Aug; 360(9333):640; author reply 640-1. PubMed ID: 12241952 [No Abstract] [Full Text] [Related] [Next] [New Search]